Sign up to our newsletter Subscribe
Challenges and Solutions for Budget Impact Analysis of Gene Therapies

Sign up to our newsletter Subscribe
On Wednesday 18th May, Dr Patricia Cubi-Molla, Economist at the Office of Health Economics, will lead an OHE Lunchtime Seminar on the topic of ‘Age, utilities, and self-reported health: issues for HTA’. On Wednesday 18th May, Dr Patricia Cubi-Molla, Economist…
On Wednesday 18th May, Dr Patricia Cubi-Molla, Economist at the Office of Health Economics, will lead an OHE Lunchtime Seminar on the topic of ‘Age, utilities, and self-reported health: issues for HTA’.
On Wednesday 18th May, Dr Patricia Cubi-Molla, Economist at the Office of Health Economics, will lead an OHE Lunchtime Seminar on the topic of ‘Age, utilities, and self-reported health: issues for HTA’.
Occasionally, in health technology assessments (HTA), the situation arises that the central estimate of patients’ HRQoL available from clinical trials exceeds that of the general population with the same age and gender. It appears unclear how HTA agencies, such as NICE, should address such an issue – should the patients’ utility scores be used in the economic evaluation of cost effectiveness, or should they be downward-adjusted to reflect their poor health relative to that of general population without the condition? The way this issue is handled has important implications for HTA and health care resource prioritisation.
This problem appears to be more likely to occur in elderly populations. One possible explanation for the patient group mean score exceeding the general population mean score is that the existence of some older people with very poor health in the general population drags down the mean. There may also be differences in the way that the same underlying state of health is interpreted by individuals of different ages. It could also be due to people of different ages having different preferences regarding health, with an individual’s views about how good or bad a given health state is reflecting their aspirations, fears and priorities, all of which may vary systematically with age. All this opens up the possibility that a technology may not be cost-effective on average but cost-effective for a sub-group whose preferences over health are more closely aligned to the benefits offered by the technology. The use of preference sub-groups can therefore increase overall health and improve efficiency by making the technology available only for the relevant sub-group, as long as that sub-group can easily be identified (such as one defined by age).
However, it is unclear whether any differences observed between age groups are driven by genuine differences in preferences or by artefacts of the technique used to elicit the preferences. Given the multitude of factors that could be driving differences in utilities, it is informative to examine the ways in which people’s valuations of hypothetical health states (e.g., using TTO) differ between methods, and from self-ratings of their own health (e.g., on the EQ VAS).
The aim of this research is to investigate several features which may explain the fact that a central estimate of HRQoL for a group of elderly patients can exceed that of the general population with the same age. Specifically, the seminar will address the following questions:
This piece of research is based on findings from a research study performed by OHE and Roche Products Ltd and funded by Roche Products Ltd. Views expressed in the seminar are those of the authors.
Patricia Cubi-Molla joined OHE in September 2015. Patricia’s main areas of research are: health-related quality of life measures, subjective well-being, cost-effectiveness thresholds, estimation of health-related outcomes, health policy evaluation, adaptation to health states, ordered choice models and theory of preferences.
Patricia obtained her PhD in Economics from the Quantitative Economics Doctorate (QED, University of Alicante) in 2009, after obtaining her BSc in Mathematics from the same university in 2002. Moving to the UK in 2009, she has been working as a Lecturer in Economics at City University London, where she has been actively involved in the Health Economics and Economic Evaluation in Health Care master programmes offered by the Department of Economics.
Further information can be obtain from Kerry Sheppard
Full invitation available here.
An error has occurred, please try again later.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!